ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2018
At a glance
- Drugs ONC 201 (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Oncoceutics
- 06 Nov 2018 According to an Oncoceutics media release, data from this study will be presented at the 2018 Annual Meeting of the Society for Neuro-Oncology (Nov 2018).
- 08 Oct 2018 Planned number of patients changed from 45 to 69.
- 02 Feb 2018 New trial record